News & Views
Perkinelmer, Inc. Announced Revenue of $387.7 Million For the Fourth Quarter
Feb 14 2006 Read 2344 Times
Full year 2005 revenue of $1.47 billion increased 3% over 2004 driven primarily by sales growth in medical imaging and genetic screening. Due to the timing of the fiscal calendar, the fourth quarter of 2004 included an additional week. Adjusting for the impact of foreign exchange, acquisitions and an average week\'s sales in the prior fiscal period, annual revenue increased 4% over 2004. Fourth quarter 2005 revenue of $387.7 million decreased 6% over the fourth quarter of 2004. Revenue in the fourth quarter 2005, excluding the impact of foreign exchange, acquisitions and the extra week, increased 4% over the fourth quarter of the prior year.
GAAP operating profit during the fourth quarter was $49.8 million. Excluding intangibles amortisation and restructuring charges, operating profit for the fourth quarter of 2005 was $64.4 million, or approximately 16.6% of revenue, up from 14.9% in the fourth quarter of 2004. This increase in fourth quarter 2005 adjusted operating margin was due primarily to an increase in operating margins of 190 basis points in Life and Analytical Sciences and a 40 basis point increase in Optoelectronics. The company also generated operating cash flow of $83.4 million in the fourth quarter of 2005, up 17% compared to operating cash flow of $71.0 million for the fourth quarter of 2004.
\"2005 was an excellent year for PerkinElmer. We made great progress on focusing our portfolio on the Health Sciences and Photonics markets, building a very strong financial capability and strengthening our growth platforms. In addition, we delivered significant increases in operating margin and EPS,\" said Gregory L. Summe, Chairman and CEO of the Company. \"We enter 2006 with a very strong balance sheet and operating momentum. Our focus this year will be to accelerate growth through continued operational improvement and increasing our investment in innovation.\"
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Articles - Choosing the Optimum Plasma Spectrochemistry Technique for Measuring Elemental Impurities in Pharmaceuticals - Blue Jacaranda Seed Oil Analysed Using Comprehensive...
View all digital editions
Oct 23 2018 Frankfurt am Main, Germany
Oct 29 2018 Moscow, Russia
Oct 31 2018 Birmingham, UK
Oct 31 2018 Shanghai, China
Oct 31 2018 Tunis, Tunisia